News

There currently aren’t any clear guidelines for how health care providers should handle discrepant—1 positive and 1 negative—HIV test results during pregnancy.

On the anniversary of the discovery of the bacterium that causes tuberculosis, world health leaders are highlighting an epidemic that kills nearly 4500 people each day across the world.

A study of MSM suggests optimizing at-home testing for STIs and HIV could increase rates of testing, while noting a need to balance convenience with educational outreach.

For the first time since 2005, the IDSA has issued an update to its treatment guidelines for asymptomatic bacteriuria.

Solving a years-old mystery, investigators have discovered that MHC-II molecules can provide a gateway for bat influenza to infect human cells.

An investigation into a Nebraska Campylobacter outbreak conjures déjà vu.

A new CDC report suggests that 80% of new HIV cases were transmitted by individuals who were unaware they had HIV or who were not receiving consistent care.

Clinicians who avoid writing antibiotics prescriptions for elderly patients with urinary tract infections may be putting those patients at risk for bloodstream infections.

Direct-acting antivirals are probably worth the price, but are there new ways to get them into patients’ hands?

A communitywide HIV prevention package including in-home testing and antiretroviral therapy reduces new infections, according to a study from the HIV Prevention Trials Network.

Sulopenem, which is a novel penem anti-infective compound with both IV and oral formulations, has been granted QIDP status for 4 new indications, totaling 7 in total.

A study presented at CROI 2019 found that interventions to support PrEP persistence for younger black MSM will be necessary in order for the full effectiveness of PrEP to be achieved.

On-demand pre-exposure prophylaxis with TDF/FTC is not associated with a clinically relevant change in kidney function the way daily PrEP use is, investigators in France found.

CROI 2019 was held March 4-7, 2018, in Seattle, Washington. The conference featured results of new studies on a variety of HIV topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

A new protocol avoids spinal taps and antibiotics in the quest for evaluating febrile infants.

Although the cause of childhood-onset type 1 diabetes remains unknown, a new study links a precursor of the condition to an abundance of certain viruses in the gut.

Ceftazidime and avibactam is now approved for the treatment of pediatric patients between 3 months and 17 years with cUTI and cIAI.

Infectious diseases were responsible for 6% of unexpected deaths over a 2-year period in Ontario, highlighting the importance of prevention strategies.

Clostridium difficile rates in stem cell transplant patients are approximately 9 times greater than in hospitalized patients, with rates about twice as high in allogeneic vs autologous transplants.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A multistate outbreak of Salmonella Schwarzengrund has been attributed to consumption of ground turkey.

Although 30% of adults with XDR TB are successfully cured or complete treatment, a new study has found that children have far more favorable outcomes and lower mortality rates.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019, in the second part of our highlight reel.

A London study shows that men infected with HIV are acquiring HCV at much lower levels than before.

Post-discharge decolonization education and bioburden reduction could be critical to reducing MRSA infections.

Hospitals that try to discourage the use of fluoroquinolones succeed at lowering prescriptions for patients admitted to the hospital, but many of those patients still leave with prescriptions for fluoroquinolones at discharge.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019.